

TRACKING YOUR SESSION ATTENDANCE

Use this worksheet to help you keep track of your session attendance. This worksheet is for your reference only and should **not** be returned to NCCN. Completion of this worksheet is **not required** to claim continuing education credit.

Attended	Time	Session	Credit (AMA/ACPE/ANCC/AAPA)
DAY 1: FRIDAY, OCTOBER 14, 2022 – All times are listed as Eastern Daylight Time (UTC/GMT -4)			
	8:00 AM – 9:20 AM	Patient Case Studies and Panel Discussion: Management of Acute Lymphoblastic Leukemia	1.25
	9:25 AM – 10:25 AM	New Treatment Options and Toxicity Management in Acute Lymphoblastic Leukemia	1.0
	10:45 AM – 11:45 AM	Treating Acute Myeloid Leukemia in 2022: Evolving Concepts and Management Strategies	1.0
	12:45 PM – 1:30 PM	Management of Systemic Amyloidosis	0.75
	1:35 PM – 2:50 PM	Treatment Decisions in Multiple Myeloma	1.25
	3:10 PM – 4:10 PM	How to Incorporate Immunotherapies in the Management of Multiple Myeloma	1.0
	4:15 PM – 5:00 PM	The Importance of Re-Vaccination After Cellular Therapy	0.75
DAY 2: SATURDAY, OCTOBER 15, 2022 – All times are listed as Eastern Daylight Time (UTC/GMT -4)			
	8:00 AM – 9:20 AM	Treatment Decisions in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	1.25
	9:25 AM – 10:10 AM	Optimizing Treatment for Relapsed/Refractory Mantle Cell Lymphoma	0.75
	10:30 AM – 11:30 AM	Debate: Transplant vs. CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	1.0
	11:35 AM – 11:55 AM	ECHELON-1: Do Updated Results Change the First-Line Treatment of Stage III-IV Classical Hodgkin Lymphoma?	0.5
	12:00 PM – 12:30 PM	Management of Advanced Systemic Mastocytosis	0.5
ONLINE ONLY SESSIONS			
	ON DEMAND	Familial/Genetic Leukemia Syndromes: Impact on Patient Care	0.75
	ON DEMAND	Hematopoietic Growth Factors: Use of Thrombopoietin Receptor Agonists in Patients with Cancer	0.75
	ON DEMAND	Management of Chronic Phase Chronic Myeloid Leukemia with Resistance to Multiple TKIs	0.75
	ON DEMAND	Managing Cardiovascular Events in Multiple Myeloma	0.25
	ON DEMAND	Emerging Treatment Options for Higher-Risk Myelodysplastic Syndromes	0.25
	ON DEMAND	Management of Polycythemia Vera and Essential Thrombocythemia	0.25
Total			14.0